ASC Executive Board – CT

[level-group-4]

ASC Executive Board:

Cytotechnologist Member

Leigh Ann Cahill, B.S., CT(ASCP)CMIAC

Marilee M. Means, Ph.D., SCT(ASCP)

Donna K. Mulford-Russell, M.S., CT(ASCP)HT, CMIAC

 Vote Now!


LEIGH ANN CAHILL, B.S., CT(ASCP)CMIAC

 

Ms. Cahill is the senior cytotechnologist/assistant supervisor at Virginia Commonwealth University Medical Center (VCUMC) where she supervises the cytopreparatory laboratory and technical quality control.  She assists in quality assurance, supply management and training residents and fellows.  She received a Bachelor of Science degree from the University of Richmond in 1981 and completed her cytology training at VCUMC in 1982.

Ms. Cahill has been active in cytology organizations starting in 1983 where she held the offices of corresponding secretary, treasurer, president-elect and president of the Virginia Society of Cytology (VSC).  Ms. Cahill became a member of the American Society of Cytopathology (ASC) in 1983.  In 1991, she was elected member of the Cytotechnology Advisory Committee (CAC).  She served as Chair of the CAC in 1994-95 and again in 1997-98.  She served on the Long Range Planning Committee and participated on the Professional Identity of the Cytotechnologist Task Force during the Cytology Education Conference in Kansas City.  She also had the honor of working on the ASC Historical Committee for the 50th Anniversary Meeting.  She also served as member and Co-Chair of the Art for Advocacy Committee and member of the Scientific Program Committee.  She is currently serving as a member of the Cytotechnology Programs Review Committee (CPRC).

Ms Cahill has published various articles in scientific journals, presented workshops and a teleconference for the ASC.  She served as a panelist for the Diagnostic Slide Seminar in 2005.  She has also presented two CAC addresses, platform and poster presentations and served as moderator for the platform sessions at various ASC Annual Scientific Meetings.

The practice of cytopathology along with the roles of cytotechnologists and pathologists are changing with the increase in technology such as image-guided screening, molecular diagnostics, direct-to-vial HPV testing and the development of HPV vaccines, etc.  The changes may not be a drastic overhaul of this profession, but it may be a move from manual microscopic screening to more image-guided or even to completely computerized screening.  Additional regulations such as proficiency testing, state licensure, the Certification Maintenance Program (CMP) for cytotechnologists and the Maintenance of Certification (MOC) for pathologists are being implemented and enforced.  These changes will require education.  Will the increased costs for the technologies and regulations, i.e. proficiency testing fees, further reduce funding for continuing education, which is essential for this profession?  A major challenge for the ASC is creating new avenues for obtaining continuing education in addition to the Annual Scientific Meeting, teleconferences, etc. that are affordable and easily accessible.

If elected to the Executive Board, Ms. Cahill’s goals are to work to keep the ASC in the forefront of the changes and challenges in this profession, to help assess and develop new educational opportunities and to be a voice for the cytotechnologist membership in regards to the changing roles that may be faced in the future.  Ms. Cahill also believes in continued support of the ASC’s cytology programs to keep them informed of the changes so they can develop curriculum that serves both the needs of their students and their communities of interests.

Ms. Cahill supports the content of the ASC guidelines, including the guidelines for review of gyn cytology samples in the context of litigation or potential litigation.  She has not served as an expert witness or consulted or testified in a medicolegal case.

 

DISCLOSURE: Ms. Cahill has no affiliation, financial or otherwise, with any corporation or company that has interest in pathology.

 


MARILEE M. MEANS, Ph.D., SCT(ASCP)

 

Dr. Marilee Means attended the University of Kansas where she received her B.S., M.A. and Ph.D. degrees.  The graduate degrees were earned in Curriculum and Instruction for Allied Health Professionals.  She attended the cytology program at the University of Kansas Medical Center and is certified as SCT(ASCP).   She has 29 years of experience in the profession, having worked as a cytology laboratory supervisor and program director of the cytotechnology program at the University of Kansas Medical Center.

She has served the ASC in a variety of positions including Associate Editor of the The ASC Bulletin, Director of the Program Faculty Seminar, Local Arrangements Committee Chairperson, member of the Laboratory Accreditation Committee, ASC representative to the CAAHEP, Commissioner from the Cytotechnology Programs Review Committee (CPRC) to CAAHEP, and Chair of the CPRC.   Additionally, she has given a variety of presentations and workshops at the ASC as well as other local, regional and national organizations.

As new technologies are incorporated in laboratories as well as in education, sound instructional principles as well as the latest in content must be emphasized.  Continued work is necessary to open up the ASC to new cytotechnologists and cytopathologists by demonstrating the value of service to the professional community.  And finally, especially now, it is vital that the community of cytotechnologists have a strong voice on the Executive Board of the ASC.  Dr. Means’ goal would be to support the development of an educationally innovative, increasingly grass roots society responsive to the needs of all of its members and to the needs of our professions.

Dr. Means strongly supports the ASC guidelines, including the guidelines for review of gyn samples in the context of litigation.  She has not been an expert witness for a cervical or gyn case nor has she done medicolegal consulting nor testified in medicolegal cases.

 

DISCLOSURE: Dr. Means is a cytotechnologist consultant to the CAP Cytopathology Committee and is an advisor to Cytyc’s Cytologystuff.com web site.

 


DONNA K. MULFORD-RUSSELL, M.S., CT(ASCP)HT, CMIAC

 

Donna K. Mulford-Russell, M.S., CT(ASCP)HT, CMIAC is a 20-year veteran at the University of Rochester Medical Center, Rochester, NY where she serves as Senior Cytotechnologist and Supervisor of the Cytopathology Residency Program.  She has her Masters Degree in Education from the University of Rochester; her Bachelor’s in Cytotechnology from SUNY Upstate Medical Center and is also a registered histotechnologist. In addition to being a Voting Member of the American Society of Cytopathology (ASC), she is a member of the IAC, ASCP, ASCT, and UNYSSC. 

Ms. Mulford-Russell has served the ASC on the Cytotechnology Advisory Committee, Membership Committee, as Associate Editor and currently the Editor of The ASC Bulletin and a member of the Cytotechnology Programs Review Committee. She is also a member of the ASCP Proficiency Testing Committee, has served on the ASCP Cytostar Committee and completed her term as Editor-in-Chief of the ASCP Tech Sample.

Ms. Mulford-Russell has specialized expertise in breast and GYN cytopathology.  Her teaching experience includes local, regional and national workshop presentations, panel luncheons, and teleconferences.  She has also authored and co-authored numerous scientific papers and publications.

Ms. Mulford-Russell is a strong supporter of expanding the cytotechnologists’ horizons through continuing education and enhancement of training programs.  She believes the growing importance of molecular pathology in our field requires expanding involvement of cytotechnologists in this area.  She stresses that it is important to avoid initiatives to limit the scope of involvement in these emerging technologies, and that it is necessary to work toward enhancing the technologists’ abilities through additional training and experience in these areas. Additionally, she notes that with the anticipated drop in gynecologic volume due to HPV testing, the DNA Pap and the FDA approval of the HPV vaccination, the workforce will ultimately need to shift to accommodate the changes in volume. 

Adaptation to change is the key to the future of cytopathology. The connection between cytology and molecular diagnostics has already commenced in labs across the country.   The ASC will need to assist in this effort and continue to support the schools and educators in their efforts to produce quality technologists for the future. Her goals in running for the Executive Board are to be actively involved in decisions that affect the membership, to provide a link to the membership and to effectively communicate those changes to our members.

Ms. Mulford-Russell fully supports the ASC guidelines.  She has not accepted medicolegal cases or served in any capacity as a consultant for such cases.  She has not testified in medicolegal cases. 

 

DISCLOSURE: Ms. Mulford-Russell has no affiliation, financial or otherwise, with any corporation or company that has interest in pathology.

[/level-group-4]